

----- 2005 30-22

7 16 -----

(2003/11/1 2003/8/16)

80 20
%70 *Proteus mirabilis*
%20 *Pr. vulgaris*

Pr.

%10 *penneri*

Tobramycin

Trimethoprim Ampicillin

Ciprofloxacin

Isolation and Identification of *Proteus* Species from Urinary Tract Infection and Study of Its Response to Antibiotics

Thikra S. Ali

*Department of Microbiology
College of Veterinary Medicine
Mosul University*

Subhi H. Khalaf

*Department of Biology
College of Science
Mosul University*

Harith Sh. Yihia

*Unit of Microbiology
Al-Raze Hospital
Mosul*

ABSTRACT

Three bacterial species of *Proteus* bacteria have been isolated from various age groups (males and females) suffering from urinary tract infection. Subsequently, the isolates were diagnosed through observation of three morphological, cultural and biochemical features. Twenty isolates out of 80 patients have been diagnosed.

The study revealed that the highest infection was caused by *Pr. mirabilis* which was 70%, while infection with *Pr. vulgaris* was only 20%. These two kinds of bacteria are widely spread specially in urinary tract infections which have rather become complex due to abnormal function and composition and patients who received catheterization. As for species *Pr. penneri* it came up to from 10%. This species is rather limited in the number of isolation and only appears in certain pathological cases.

The response of antibiotic sensitivity tests has shown that the isolates were sensitive to Tobramycin, Ciprofloxacin and resistance to Ampicillin, Trimethoprim.

Proteaceae

Proteus

Phenylalanine deaminase

Swarming

Hauser

Proteus

. (Penner, 1981)

Pr. *Pr. myxofaciens* *Pr. vulgaris* *Pr. mirabilis*

.(Holt *et al.*, 1994) *penneri*

.(Cook *et al.*, 1995)

UPEC

.....

.(Foxman *et al.*, 1995)*Pr. mirabilis*.(Mobley *et al.*, 1994; Herias *et al.*, 1997).(Huovinen *et al.*, 1995)

80

Oxoid BioMerieux

24 ° 37

(3-2)

Pr.

.(Macfaddin, 1985)

*Pr. penneri**vulgaris*

(Baron and Finegold, 1990)

BioMerieux

API20E

11

(Cruickshank, 1975)

Oxoid

.(Vandepitte *et al.*, 1991)

(Vandepitte *et al.*, 1991)³ 5(Bauer *et al.*, 1966)

(5-3)

³ 0.6

(Macferland Tube No. 1)

³ / $(10^8 \times 1)$ %1 ³ 10

-

(5-3)

Muller-Hinton Agar

24 ° 37

(Vandepitte *et al.*, 1991)

:

Gentamycin (5 µg) Ciprofloxacin (50 µg) Carbencillin (10 µg) Ampicillin
 (30 µg) Chloramphenicol (30 µg) Tetracycline (10 µg) Tobramycin (10 µg)
 (300 Nitrofuration (25 µg) Trimethoprim (5 µg) Rifampicin (30 µg) Nalidixic acid
 . µg)

:

80

20

(1)


:1

%			
70	14	<i>Proteus mirabilis</i>	1
20	4	<i>Proteus vulgaris</i>	2
10	2	<i>Proteus penneri</i>	3
100	20		

(2)


:2

<i>Proteus</i>					()	
<i>Pr. mirabilis</i>	+				25	1
<i>Pr. mirabilis</i>	+				29	2
<i>Pr. mirabilis</i>	-				19	3
<i>Pr. vulgaris</i>	+				44	4
<i>Pr. vulgaris</i>	+				3	5
<i>Pr. mirabilis</i>	-				36	6
<i>Pr. mirabilis</i>	-				7	7
<i>Pr. mirabilis</i>	-				22	8
<i>Pr. mirabilis</i>	-				10	9
<i>Pr. mirabilis</i>	-				18	10
<i>Pr. mirabilis</i>	-				26	11
<i>Pr. mirabilis</i>	+				32	12
<i>Pr. mirabilis</i>	-				38	13
<i>Pr. vulgaris</i>	+				39	14
<i>Pr. mirabilis</i>	+				30	15
<i>Pr. vulgaris</i>	+				22	16
<i>Pr. mirabilis</i>	-				2	17
<i>Pr. mirabilis</i>	+				8	18
<i>Pr. penneri</i>	-				5	19
<i>Pr. penneri</i>	-				6	20



Proteus mirabilis

API 20E :1



Proteus vulgaris

API 20E :2

:


(1)

%85 %90 Trimethoprim Ampicillin
%50 %55 Gentamycin Nitrofuration

.....

Ciprofloxacin Tobramycin

%90 %100



:2

Pr. mirabilis(Muhldorfer *et al.*, 2001)Collee *et al.*, 1996;)(Zunino *et al.*, 1999; Liaw *et al.*, 2000*Pr. vulgaris*(Koneman *et al.*, 1997)*Pr. penneri*

%12	(%20-10)	(Warren, 1996)
		(Warren, 1996)
		(Senior, 1999)
		.(Chippendale <i>et al.</i> , 1994)
		.(Allison <i>et al.</i> , 1992)
		(Huovinen <i>et al.</i> , 1996)
Nitrofuration		(Bush <i>et al.</i> , 1995)
	.Ampicillin	Ciprofloxacin
		Gentamycin

- Allison, C., Coleman, N., Jones, P.L. and Hughes, C., 1992. Ability of *Proteus mirabilis* to invade human urothelial cells is coupled to motility and swarming differentiation. *Infect. Immun.*, Vol.60, pp.4740-4746.
- Baron, E.J. and Finegold, S.M., 1990. Baily and Scott's Diagnostic Microbiology. 8th ed., C.V. Mosby Company, St. Louis, USA, pp.386-389.
- Bauer, A.W., Kirby, W.A.M., Sherris, J.S. and Turk, M., 1966. Antibiotic susceptibility testing by a standardized single disk method. *Am. J. Clin. Pathol.*, Vol.45, pp.493-496.
- Bush, K., Jacoby, G.A. and Medeiros, A.A., 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. *Antimicrob. Agents. Chemother.*, Vol.39, pp.1211-1233.
- Chippendale, G.R., Warren, J.W., Trifillis, A.L. and Mobley, H.L., 1994. Internalization of *Proteus mirabilis* by human renal epithelial cells. *Infect. Immun.*, Vol.92, pp.3115-3121.
- Collee, J.G., Fraser, A.G., Marmion, B.P. and Simmons, A., 1996. Mackie and McCartney Practical Medical Microbiology. 14th ed., Churchill Livingstone Inc., New York, USA, pp.372-374.

- Cook, S.W., Mody, N., Valle, J. and Hull, R., 1995. Molecular cloning of *Proteus mirabilis* uroepithelial cell adherence (uca) genes. *Infect. Immun.*, Vol.63, pp.2082-2086.
- Cruickshank, R., Duguid, J.P., Marmion, B.P. and Swain, R.H.A., 1975. Medical Microbiology. 12th ed., Vol. 2, The Practice of Medical Microbiology, Churchill Livingstone, Edinburg, London and New York.
- Foxman, B., Zhang, L., Palin, K., Tallman, P. and Marrs, C.E., 1995. Bacterial virulence characteristics of *Escherichia coli* isolates from first-time urinary tract infection. *J. Infect. Dis.*, Vo;171, pp.1514-1521.
- Herias, M.V., Midtvedt, T., Hanson, A. and Wold, A.E., 1997. *Escherichia coli* K5 capsule expression enhances colonization of the large intestine in the gnotobiotic rat. *Infect. Immun.*, Vol.65, pp.531-536.
- Holt, J.G., Krieg, N.R., Sneath, P.H.A., Staley, J.T. and Williams, S.T., 1994. Bergey's Manual of Determinative Bacteriology. 9th ed. Williams and Wilkins Comp. USA, Baltimore.
- Huovinen, P., Sundstrom, L., Swedberg, G. and Skold, O., 1995. Trimethoprim and sulphonamide resistance. *Antimicrob. Agents Chemother.*, Vol.39, pp.279-289.
- Koneman, E.W., Allen, S.D., Janda, W.M., Schreckenberger, P.C. and Winn, W.C., 1997. Color Atlas and Textbook of Diagnostic Microbiology. 5th ed., Lippincott-Raven Publisher, Philadelphia, USA, pp.211-213.
- Liaw, S.J., Lai, H.C., However, S.W., Luh, K.T. and Wang, W.B., 2000. Inhibition of virulence factor expression and swarming differentiation in *Proteus mirabilis* by p-nitrophenylglycerol. *J. Med. Microbiol.*, Vol.49, pp.725-731.
- Macfaddin, J.F., 1985. Biochemical Tests for Identification of Medical Bacteria. 2nd ed. Waverly Press, Inc., Baltimore, USA, p.4-10, 36-47, 173-181.
- Mobely, H.L.T., Island, D. and Massad, G. 1994. Virulence determinants if uropathogenic *Escherichia coli* and *Proteus mirabilis*. *Kidney Int. Suppl.*, Vol.47, pp.129-136.
- Muhldorfer, I., Ziebuhr, W. and Hacker, J., 2001. *Escherichia coli* in urinary tract infections. Academic Press. Springer, Verlang. Berlin. Germabny, pp. 1-26.
- Penner, J.L., 1981. The Tribe Proteeae. In: Starrm *et al.* The Prokaryotes a Handbook on Habitates, Isolation and Identification of Bacteria. Springer verlag, Berlin.
- Senior, B.W., 1999. Investigation of the types and characteristics of the proteolytic enzymes formed by diverse strains of *Proteus* species. *J. Med. Microbiol.*, Vol.48, pp.623-628.
- Vandepitte, J., Engback, K., Piot, P. and Hench, C.C., 1991. Basic Laboratory Procedures in Clinical Bacteriology. World Health Organization, Geneva, Switzerland, pp. 31-36, 78-95.
- Warren, J.W., 1996. Clinical presentation and epidemiology of urinary tract infections. In: Mobleg, H.L./T., Warren, J.W. (eds). Urinary Tract Infections: Molecular Pathogenesis and Clinical Management. Washington, DC: American Society for Microbiology, pp. 3-27.
- Zunino, P., Piccini, C. and Fajardo, C.L., 1999. Growth, cellular differentiation and virulence factor expression by *Proteus mirabilis* in vitro and in vivo. *J. Med. Microbiol.*, Vol.48, pp.527-534.